The global saliva-based screening market is projected to reach a value of US$ 374.9 million in 2024. It is expected to grow at a CAGR of 8.0% between 2024 and 2034, ultimately reaching an estimated worth of US$ 810.9 million by 2034.

The increasing demand for saliva-based screening is driven by its advantages as a non-invasive and less intrusive alternative to blood-based diagnostics. This method is especially valuable in point-of-care environments and remote or underserved regions with limited healthcare access. Additionally, saliva collection is simpler and quicker than traditional blood draws, enabling more frequent health monitoring while easing the strain on healthcare systems.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9740

What are Some Lucrative Opportunities in the Saliva-based Screening Market?

"Ongoing Research Expands Saliva-based Screening's Diagnostic Potential from Personalized Medicine to Clinical Trials"

Current research is uncovering new biomarkers within saliva, broadening the spectrum of diseases and conditions that saliva-based screening can detect. Technological advancements are enabling more detailed biomarker profiling, paving the way for personalized medicine approaches. This means treatments could be customized based on an individual's unique saliva profile, enhancing therapeutic effectiveness.

Such innovations hold significant promise, particularly in resource-constrained environments or during public health crises, where rapid and accurate diagnostics are critical. Additionally, saliva-based screening is increasingly being integrated into clinical trials, offering a non-invasive tool for monitoring patient responses and disease progression, further expanding its market potential.

Country-wise Insights

The saliva-based screening market has a strong presence in North America and East Asia. North America is projected to hold a significant 33.5% share of the global market in 2024, with an anticipated CAGR of 7.6% throughout the forecast period.

East Asia also commands a notable portion of the market, accounting for an estimated 19.1% share in 2024. The region is expected to experience robust growth, with a projected CAGR of 9.3% during the same period, reflecting increasing adoption and demand for saliva-based screening technologies.

Category-wise Insights

Saliva-based screening is rapidly gaining traction among patients, manufacturers, and producers who value its non-invasive nature. The simplicity of sample collection, combined with its versatility in diagnosing a wide range of health conditions, makes saliva-based screening an attractive and dependable diagnostic option.

This growing acceptance enables manufacturers and producers to scale up production, making these tests more affordable and widely accessible for patients. As awareness spreads among healthcare providers, patients, and industry stakeholders about the advantages of saliva-based diagnostics, demand for these tests is expected to rise steadily.

Competitive Landscape

Prominent players in the saliva-based screening market include Thermo Fisher Scientific, Inc., Neogen Corporation, Abbott, Sarstedt AG & Co. KG, Autogen, Inc., Oasis Diagnostics, Porex, Salimetrics, LLC, Takara Bio, Inc., Arcis Bio, and Orasure Technologies.

Innovative companies such as Molbio Diagnostics, Testi Technologies, and emerging firms like Salilistic are playing pivotal roles in driving technological breakthroughs. These innovations encompass rapid point-of-care saliva testing devices, expanding diagnostic uses beyond infectious diseases, and integrating advanced genomic and proteomic analyses. Market leaders are heavily investing in research and development to improve diagnostic accuracy, identify new biomarkers, and broaden the range of saliva-based screening applications.

Recent Developments:

On December 15, 2023, Molbio Diagnostics, based in Goa, partnered with Finland's Testi Technologies to commercialize PROMILLESS, a saliva-based self-test kit for measuring blood alcohol content. This collaboration aims to improve accessibility and advance diagnostic technology.
On August 28, 2023, researchers investigated automated saliva-based PCR testing for COVID-19 surveillance, publishing findings on the medRxiv preprint server detailing its implementation in an educational setting.
On June 21, 2023, Salilistic launched the world's first saliva-based pregnancy test in the UK, marking a significant leap in home pregnancy detection by eliminating the need for urine samples.

Browse Full Report: https://www.factmr.com/report/saliva-based-screening-market

Segmentation of the Saliva-based Screening Market

By Product Type :
Saliva Collection Kits
Saliva Nucleic Acid Purification Kits,
Saliva Based Detection Kits
By Purpose :
Research Use Only
Diagnostics
By Application :
Infection Analysis/Detection (Non- COVID)
Genomic Analysis
Proteomics
Pharmacogenomics
Liquid biopsy
By End User :
Hospitals & Clinics
Diagnostic Laboratories
Academic and Research Institutes
Biopharmaceuticals and CROs
By Region :
North America
Latin America
Europe
East Asia
South Asia & Oceania
Middle East & Africa

Check out More Related Studies Published by Fact.MR:

Esophageal Stents Market
https://www.factmr.com/report/esophageal-stents-market
Artificial Kidney Market
https://www.factmr.com/report/artificial-kidney-market
OTC Pediatric Healthcare Market
https://www.factmr.com/report/257/otc-pediatric-healthcare-market
Microdontia Treatment Market
https://www.factmr.com/report/microdontia-treatment-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: [email protected]

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.